Leticia Toledo-Sherman
Corporate Officer/Principal at LymphoSign, Inc.
Leticia Toledo-Sherman active positions
| Companies | Position | Start | End |
|---|---|---|---|
LymphoSign, Inc.
 LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Corporate Officer/Principal | 2004-07-31 | - |
Career history of Leticia Toledo-Sherman
Former positions of Leticia Toledo-Sherman
| Companies | Position | Start | End |
|---|---|---|---|
| MDS Proteomics, Inc. | Corporate Officer/Principal | - | - |
Kinetix Pharmaceuticals, Inc.
 Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity | Corporate Officer/Principal | - | - |
Training of Leticia Toledo-Sherman
| The State University of New York | Doctorate Degree |
Statistics
International
| Canada | 3 |
| United States | 3 |
Operational
| Corporate Officer/Principal | 3 |
| Doctorate Degree | 1 |
Sectoral
| Commercial Services | 3 |
| Health Technology | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
LymphoSign, Inc.
LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Health Technology |
Kinetix Pharmaceuticals, Inc.
Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity | Commercial Services |
| MDS Proteomics, Inc. | Commercial Services |
